Skip to main content

CORRECTION article

Front. Pharmacol., 28 April 2022
Sec. Cardiovascular and Smooth Muscle Pharmacology
Volume 13 - 2022 | https://doi.org/10.3389/fphar.2022.910421

Corrigendum: Propofol Protects Myocardium From Ischemia/Reperfusion Injury by Inhibiting Ferroptosis Through the AKT/p53 Signaling Pathway

This article is a correction to:

  1. Propofol Protects Myocardium From Ischemia/Reperfusion Injury by Inhibiting Ferroptosis Through the AKT/p53 Signaling Pathway

    1. Read original article
Shengqiang LiShengqiang Li1Zhen LeiZhen Lei1Xiaomei YangXiaomei Yang1Meng ZhaoMeng Zhao1Yonghao HouYonghao Hou1Di WangDi Wang2Shuhai TangShuhai Tang1Jingxin Li Jingxin Li3*Jingui Yu Jingui Yu1*
  • 1Department of Anesthesiology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
  • 2Department of Anesthesiology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
  • 3Department of Physiology, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan, China

A Corrigendum on
Propofol Protects Myocardium From Ischemia/Reperfusion Injury by Inhibiting Ferroptosis Through the AKT/p53 Signaling Pathway

by Li, S., Lei, Z., Yang, X., Zhao, M., Hou, Y., Wang, D., Tang, S., Li, J. and Yu, J. (2022). Front. Pharmacol. 13:841410. doi: 10.3389/fphar.2022.841410

In the published article, there was an error regarding the affiliation for Jingxin Li. The full designation for affiliation 3 is “Department of Physiology, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China”.

There was an error in the Funding statement. The correct name for the third listed funder is “Key Research and Development Program of Shandong Province (No. 2018GSF118079)”.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: Akt, ferroptosis, heart, ischemia/reperfusion injury, propofol, p53

Citation: Li S, Lei Z, Yang X, Zhao M, Hou Y, Wang D, Tang S, Li J and Yu J (2022) Corrigendum: Propofol Protects Myocardium From Ischemia/Reperfusion Injury by Inhibiting Ferroptosis Through the AKT/p53 Signaling Pathway. Front. Pharmacol. 13:910421. doi: 10.3389/fphar.2022.910421

Received: 01 April 2022; Accepted: 12 April 2022;
Published: 28 April 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Li, Lei, Yang, Zhao, Hou, Wang, Tang, Li and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jingxin Li, ljingxin@sdu.edu.cn; Jingui Yu, yujingui1109@126.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.